Surface death-receptor expression on CD4 and CD8 T cells from healthy donors and HIV-infected patients
| . | HIV− . | HIV+ . | ||||
|---|---|---|---|---|---|---|
| Ex vivo . | Medium . | Anti-CD3 . | Ex vivo . | Medium . | Anti-CD3 . | |
| CD4 T cells | ||||||
| CD95 | ||||||
| % | 25 ± 5.7 | 24.3 ± 9.5 | 54.5 ± 23*,† | 32.3 ± 13 | 31.4 ± 12.8 | 54.4 ± 18.4* |
| MFI | (3.7 ± 1.0) | (3.9 ± 2.2) | (10.4 ± 5.0)* | (5.2 ± 2.8) | (5.7 ± 3.3) | (10.4 ± 5.3)* |
| TNFR1 | ||||||
| % | 1.8 ± 2.6 | 1.4 ± 1.4 | 9.3 ± 10.8 | 1.3 ± 0.8 | 1.7 ± 0.8 | 6.3 ± 5.6 |
| MFI | (0.5 ± 0.9) | (0.6 ± 0.7) | (1.9 ± 1.4)§ | (< 0.1 ± 0.5) | (0.2 ± 0.2) | (0.9 ± 0.9) |
| TNFR2 | ||||||
| % | 3.8 ± 2.2 | 5.2 ± 2.0 | 46.5 ± 13.3† | 4.8 ± 1.6 | 6.0 ± 2.4 | 36.4 ± 11.8† |
| MFI | (1.0 ± 0.6) | (1.3 ± 0.9) | (8.9 ± 3.6)† | (1.2 ± 1.0) | (1.3 ± 0.9) | (8.1 ± 5.4)§ |
| CD8 T cells | ||||||
| CD95 | ||||||
| % | 19.7 ± 7.1 | 22.1 ± 9.2 | 50.3 ± 15.6* | 32.5 ± 15.7 | 33.2 ± 14.8 | 49.8 ± 18* |
| MFI | (3.1 ± 0.9) | (3.5 ± 1.5) | (8.2 ± 3.5)* | (4.6 ± 2.1) | (4.7 ± 2.2) | (7.8 ± 4.0)* |
| TNFR1 | ||||||
| % | 2.1 ± 2.3 | 2.3 ± 2.5 | 7.7 ± 6.7* | 1.3 ± 0.3 | 2.2 ± 1.1 | 5 ± 2.9 |
| MFI | (1.1 ± 0.7) | (1.1 ± 0.9) | (2.0 ± 1.1) | (0.4 ± 0.1) | (0.8 ± 0.5) | (0.8 ± 0.3) |
| TNFR2 | ||||||
| % | 8.2 ± 5.5 | 8.3 ± 5.2 | 35.2 ± 12.6† | 6.4 ± 1.5 | 9.9 ± 6.2 | 34.2 ± 9.7† |
| MFI | (2.2 ± 1.0) | (2.7 ± 1.4) | (6.9 ± 3.2)* | (1.7 ± 0.6) | (2.3 ± 1.1) | (7.6 ± 4.4)* |
| . | HIV− . | HIV+ . | ||||
|---|---|---|---|---|---|---|
| Ex vivo . | Medium . | Anti-CD3 . | Ex vivo . | Medium . | Anti-CD3 . | |
| CD4 T cells | ||||||
| CD95 | ||||||
| % | 25 ± 5.7 | 24.3 ± 9.5 | 54.5 ± 23*,† | 32.3 ± 13 | 31.4 ± 12.8 | 54.4 ± 18.4* |
| MFI | (3.7 ± 1.0) | (3.9 ± 2.2) | (10.4 ± 5.0)* | (5.2 ± 2.8) | (5.7 ± 3.3) | (10.4 ± 5.3)* |
| TNFR1 | ||||||
| % | 1.8 ± 2.6 | 1.4 ± 1.4 | 9.3 ± 10.8 | 1.3 ± 0.8 | 1.7 ± 0.8 | 6.3 ± 5.6 |
| MFI | (0.5 ± 0.9) | (0.6 ± 0.7) | (1.9 ± 1.4)§ | (< 0.1 ± 0.5) | (0.2 ± 0.2) | (0.9 ± 0.9) |
| TNFR2 | ||||||
| % | 3.8 ± 2.2 | 5.2 ± 2.0 | 46.5 ± 13.3† | 4.8 ± 1.6 | 6.0 ± 2.4 | 36.4 ± 11.8† |
| MFI | (1.0 ± 0.6) | (1.3 ± 0.9) | (8.9 ± 3.6)† | (1.2 ± 1.0) | (1.3 ± 0.9) | (8.1 ± 5.4)§ |
| CD8 T cells | ||||||
| CD95 | ||||||
| % | 19.7 ± 7.1 | 22.1 ± 9.2 | 50.3 ± 15.6* | 32.5 ± 15.7 | 33.2 ± 14.8 | 49.8 ± 18* |
| MFI | (3.1 ± 0.9) | (3.5 ± 1.5) | (8.2 ± 3.5)* | (4.6 ± 2.1) | (4.7 ± 2.2) | (7.8 ± 4.0)* |
| TNFR1 | ||||||
| % | 2.1 ± 2.3 | 2.3 ± 2.5 | 7.7 ± 6.7* | 1.3 ± 0.3 | 2.2 ± 1.1 | 5 ± 2.9 |
| MFI | (1.1 ± 0.7) | (1.1 ± 0.9) | (2.0 ± 1.1) | (0.4 ± 0.1) | (0.8 ± 0.5) | (0.8 ± 0.3) |
| TNFR2 | ||||||
| % | 8.2 ± 5.5 | 8.3 ± 5.2 | 35.2 ± 12.6† | 6.4 ± 1.5 | 9.9 ± 6.2 | 34.2 ± 9.7† |
| MFI | (2.2 ± 1.0) | (2.7 ± 1.4) | (6.9 ± 3.2)* | (1.7 ± 0.6) | (2.3 ± 1.1) | (7.6 ± 4.4)* |
Surface expression of death receptors on CD4 and CD8 T cells from control donors and HIV-infected patients was analyzed by flow cytometry either ex vivo or following overnight incubation in medium or in the presence of coated anti-CD3 mAbs. Data represent mean ± SD from 7 HIV-1–infected patients and 5 control individuals.
P < .05 versus medium.
P < .02 versus medium (Mann-Whitney test).